Ovarian Cancer Recurrent Clinical Trials
2 recruiting trials for Ovarian Cancer Recurrent. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Ovarian Cancer Recurrent clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Early Phase 1 is the largest group at 50% (1 studies); the largest phase groups are Early Phase 1: 1, Phase 2: 1.
Research is led by Second Xiangya Hospital of Central South University (1), InxMed (Shanghai) Co., Ltd. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Disitamab Vedotin in Combination With Anlotinib Hydrochloride (drug, 1 trial), followed by IN10018, Placebo of IN10018.
Track Ovarian Cancer Recurrent trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the...
Ovarian cancer is one of the three major malignant tumors of the female reproductive system. Even if newly diagnosed ovarian cancer patients undergo ideal tumor cell reduction...
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment...
This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Ovarian Cancer Recurrent, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Ovarian Cancer Recurrent, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Ovarian Cancer Recurrent, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.